Cargando…

Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab

Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaviano, Giancarlo, De Corso, Eugenio, Cantone, Elena, Ciofalo, Andrea, Saccardo, Tommaso, Bernardi, Riccardo, Mairani, Edoardo, Montuori, Claudio, Roccuzzo, Giuseppe, Soldati, Livia, Randon, Benedetto, Zampollo, Sonny, Chicco, Alessandra Di, Visconti, Francesca, Scarpa, Bruno, Nicolai, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962970/
https://www.ncbi.nlm.nih.gov/pubmed/36836468
http://dx.doi.org/10.3390/jpm13020234
_version_ 1784896134602293248
author Ottaviano, Giancarlo
De Corso, Eugenio
Cantone, Elena
Ciofalo, Andrea
Saccardo, Tommaso
Bernardi, Riccardo
Mairani, Edoardo
Montuori, Claudio
Roccuzzo, Giuseppe
Soldati, Livia
Randon, Benedetto
Zampollo, Sonny
Chicco, Alessandra Di
Visconti, Francesca
Scarpa, Bruno
Nicolai, Piero
author_facet Ottaviano, Giancarlo
De Corso, Eugenio
Cantone, Elena
Ciofalo, Andrea
Saccardo, Tommaso
Bernardi, Riccardo
Mairani, Edoardo
Montuori, Claudio
Roccuzzo, Giuseppe
Soldati, Livia
Randon, Benedetto
Zampollo, Sonny
Chicco, Alessandra Di
Visconti, Francesca
Scarpa, Bruno
Nicolai, Piero
author_sort Ottaviano, Giancarlo
collection PubMed
description Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3, 6 and 12 months from the first administration and were considered for this study. At baseline (T0) and at each follow-up, patients underwent nasal endoscopy and completed the sinonasal outcome test (SNOT)-22, a visual analogue scale (VAS) for smell/nasal obstruction, peak nasal inspiratory flow (PNIF) and the Sniffin’ Sticks identification test (SSIT). The aim of the present study was to evaluate the effects of dupilumab in patients with severe uncontrolled CRSwNP on recovering nasal obstruction and smell impairment. Moreover, the method between PNIF and SSIT with the highest correlation with patients’ response to dupilumab was evaluated. One hundred forty-seven patients were included. All parameters improved during treatment (p < 0.001). At T0, no correlations were found between PNIF and nasal symptoms. Nevertheless, during the following evaluations significant correlations between PNIF changes and both nasal symptoms and NPS were observed (p < 0.05). At T0, SSIT did not correlate with SNOT-22. Similarly to PNIF, during the follow-up SSIT changes significantly correlated with nasal symptom and NPS (p < 0.05). Comparing PNIF and SSIT correlations with SNOT-22 and NPS, PNIF showed a higher correlation with both. Dupilumab improves nasal obstruction and the sense of smell. PNIF and SSIT are effective tools in monitoring patients’ response to dupilumab.
format Online
Article
Text
id pubmed-9962970
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99629702023-02-26 Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab Ottaviano, Giancarlo De Corso, Eugenio Cantone, Elena Ciofalo, Andrea Saccardo, Tommaso Bernardi, Riccardo Mairani, Edoardo Montuori, Claudio Roccuzzo, Giuseppe Soldati, Livia Randon, Benedetto Zampollo, Sonny Chicco, Alessandra Di Visconti, Francesca Scarpa, Bruno Nicolai, Piero J Pers Med Communication Chronic rhinosinusitis with nasal polyps (CRSwNP) in the most severe forms is associated with a poor quality of life. Dupilumab has been suggested as an add-on treatment option for severe CRSwNP. Severe CRSwNP patients treated with dupilumab in different rhinological units were followed up at 1, 3, 6 and 12 months from the first administration and were considered for this study. At baseline (T0) and at each follow-up, patients underwent nasal endoscopy and completed the sinonasal outcome test (SNOT)-22, a visual analogue scale (VAS) for smell/nasal obstruction, peak nasal inspiratory flow (PNIF) and the Sniffin’ Sticks identification test (SSIT). The aim of the present study was to evaluate the effects of dupilumab in patients with severe uncontrolled CRSwNP on recovering nasal obstruction and smell impairment. Moreover, the method between PNIF and SSIT with the highest correlation with patients’ response to dupilumab was evaluated. One hundred forty-seven patients were included. All parameters improved during treatment (p < 0.001). At T0, no correlations were found between PNIF and nasal symptoms. Nevertheless, during the following evaluations significant correlations between PNIF changes and both nasal symptoms and NPS were observed (p < 0.05). At T0, SSIT did not correlate with SNOT-22. Similarly to PNIF, during the follow-up SSIT changes significantly correlated with nasal symptom and NPS (p < 0.05). Comparing PNIF and SSIT correlations with SNOT-22 and NPS, PNIF showed a higher correlation with both. Dupilumab improves nasal obstruction and the sense of smell. PNIF and SSIT are effective tools in monitoring patients’ response to dupilumab. MDPI 2023-01-28 /pmc/articles/PMC9962970/ /pubmed/36836468 http://dx.doi.org/10.3390/jpm13020234 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Ottaviano, Giancarlo
De Corso, Eugenio
Cantone, Elena
Ciofalo, Andrea
Saccardo, Tommaso
Bernardi, Riccardo
Mairani, Edoardo
Montuori, Claudio
Roccuzzo, Giuseppe
Soldati, Livia
Randon, Benedetto
Zampollo, Sonny
Chicco, Alessandra Di
Visconti, Francesca
Scarpa, Bruno
Nicolai, Piero
Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title_full Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title_fullStr Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title_full_unstemmed Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title_short Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab
title_sort measuring nasal patency and the sense of smell in crswnp patients treated with dupilumab
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962970/
https://www.ncbi.nlm.nih.gov/pubmed/36836468
http://dx.doi.org/10.3390/jpm13020234
work_keys_str_mv AT ottavianogiancarlo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT decorsoeugenio measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT cantoneelena measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT ciofaloandrea measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT saccardotommaso measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT bernardiriccardo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT mairaniedoardo measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT montuoriclaudio measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT roccuzzogiuseppe measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT soldatilivia measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT randonbenedetto measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT zampollosonny measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT chiccoalessandradi measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT viscontifrancesca measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT scarpabruno measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab
AT nicolaipiero measuringnasalpatencyandthesenseofsmellincrswnppatientstreatedwithdupilumab